Market Cap (In USD)
2.61 Billion
Revenue (In USD)
1.86 Million
Net Income (In USD)
-95.99 Million
Avg. Volume
534.52 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 14.2-51.61
- PE
- -
- EPS
- -
- Beta Value
- 1.025
- ISIN
- US92337R1014
- CUSIP
- 92337R101
- CIK
- 1831828
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Marshall W. Fordyce M.D.
- Employee Count
- -
- Website
- https://veratx.com
- Ipo Date
- 2021-05-14
- Details
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
More Stocks
-
2303
-
VEL
-
200570Changchai Company, Limited
200570
-
SHIM
-
2491
-
2362Clevo Co.
2362
-
3526
-
BSSP